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Claudia Linsenmeier1, Daniel Thoennessen1, Laura Negretti1, Jean-Pierre Bourquin2, Tino Streller1, 
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Purpose: To retrospectively analyze patient characteristics, treatment, and treatment outcome of pediatric patients with hema-
tologic diseases treated with total body irradiation (TBI) between 1978 and 2006.
Patients and Methods: 32 pediatric patients were referred to the Department of Radiation-Oncology at the University of Zurich 
for TBI. Records of regular follow-up of 28 patients were available for review. Patient characteristics as well as treatment outcome 
regarding local control and overall survival were assessed. A total of 18 patients suffered from acute lymphoblastic leukemia 
(ALL), 5 from acute and 2 from chronic myelogenous leukemia, 1 from non-Hodgkin lymphoma, and 2 from anaplastic anemia. 
The cohort consisted of 15 patients referred after first remission and 13 patients with relapsed leukemia. Mean follow-up was 34 
months (2–196 months) with 15 patients alive at the time of last follow-up. Eight patients died of recurrent disease, 1 of graft 
vs. host reaction, 2 of sepsis, and 2 patients died of a secondary malignancy.
Results: The 5-year overall survival rate (OS) was 60%. Overall survival was significantly inferior in patients treated after relapse 
compared to those treated for newly diagnosed leukemia (24% versus 74%; p=0.004). At the time of last follow-up, 11 patients 
survived for more than 36 months following TBI. Late effects (RTOG ≥3) were pneumonitis in 1 patient, chronic bronchitis in 1 
patient, cardiomyopathy in 2 patients, severe cataractogenesis in 1 patient (48 months after TBI with 10 Gy in a single dose) 
and secondary malignancies in 2 patients (36 and 190 months after TBI). Growth disturbances were observed in all patients 
treated prepubertally. In 2 patients with identical twins treated at ages 2 and 7, a loss of 8% in final height of the treated twin 
was observed.
Conclusion: As severe late sequelae after TBI, we observed 2 secondary malignancies in 11 patients who survived in excess of 36 
months. However, long-term morbidity is moderate following treatment with the fractionated TBI at the low-dose rate that was 
generally used here. Conditioning for bone marrow transplantation without radiation is an attractive option, but is not sufficiently 
effective to completely replace TBI for the most common pediatric indications.
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Ganzkörperbestrahlung (TBI) in der Pädiatrie – 30 Jahre Erfahrungen mit Niedrig-Dosisraten-Bestrahlung
Ziel: Retrospektive Analyse von Patientencharakteristika, Behandlung und Ergebnis bei Kindern mit hämatologischen Erkran-
kungen, die zwischen 1978 und 2006 mit Ganzkörperbestrahlung behandelt wurden.
Patienten und Methodik: 32 Kinder wurden unserer Klinik zur TBI zugewiesen, 28 Krankengeschichten waren zugänglich (n=28). 
18 Patienten litten unter akuter lymphoblastischer Leukämie (ALL), 5 unter akuter (AML) und 2 unter chronisch myeloischer Leuk-
ämie (CML), einer unter Non-Hodgkin-Lymphom und zwei unter aplastischer Anämie. 15 Patienten wurden nach erster Remission 
zugewiesen, 13 mit Rezidiv. Bei der letzten Kontrolle lebten noch 15 Patienten (mean 34 Monate (2–196 Monate). Acht Patienten 
sind an einem Rezidiv verstorben, einer an einer Graft-versus-host Erkrankung, zwei an Sepsis und zwei an Sekundärtumoren.
Resultate: Das 5-Jahres Gesamtüberleben lag bei 60%. Das Gesamtüberleben war signifikant (p=0.004) niedriger bei Patienten, 
die nach einem Rezidiv behandelt wurden (24%), als bei solchen die bei Erstdiagnose behandelt wurden (74%). Spättoxizität 
RTOG >=3 waren eine Pneumonitis bei 1 Patienten, eine chronische Bronchitis bei einem Patienten, Kardiomyopathie bei 2 
Patienten, eine Katarakt bei einem Patienten (48 Monate nach TBI mit 10Gy Einzeldosis) und Sekundärtumore bei 2 Patienten. 
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Introduction
Hematopoetic stem cell transplantation is the treatment of 
choice for many hematological malignancies. Since the first 
successful bone marrow transplantations in the 1950s, total 
body irradiation (TBI) remained the mainstay of condition-
ing regimens until the late 1980s in both pediatric and adult 
patients [14, 22]. In the late 1970s, the technique changed from 
high-dose single fractions to fractionated regimens [20]. The 
incidence of the often lethal veno-occlusive disease (VOD) of 
the liver was dramatically reduced with fractionated regimens 
[11, 12]. In the 1980s, dose rates were reduced resulting in a 
further decrease in late effects, especially cataractogenesis, 
renal toxicity, and interstitial pneumonitis [1, 7, 16] . Never-
theless, severe long-term sequelae, especially the induction of 
secondary malignancy, hormonal dysregulation, reproductive 
insufficiency, as well as growth retardation and the develop-
ment of osteochondromas in pediatric patients remained an 
issue [15, 21, 23, 29].
In the 1990s, a couple of prospective randomized studies 
were initiated in which TBI was compared to chemotherapy-
only regimens, usually based on busulfan and cyclophospha-
mide. However, TBI proved to be superior as far as overall sur-
vival (OS), disease-free survival (DFS), graft vs. host reaction 
(GvHR) and VOD incidence were concerned [5, 6, 13, 17, 28]. 
Therefore, total body irradiation has remained the corner-
stone of conditioning regimens in pediatric hematologic dis-
eases [30] despite the risk of possible late consequences.
The TBI technique differs dramatically between institu-
tions. Most essential is the generation of one homogenous 
large field in order to prevent overdosage due to overlapping 
adjacent fields. Irregularities of body contour, tissue hetero-
geneity, and the difficulties of internal scatter impose major 
radiation delivery and treatment planning difficulties [8]. The 
applied TBI technique and its dosimetry, however, significant-
ly affect the success of bone marrow transplantation (BMT) 
and the rate of complications [18, 22].
We reviewed the records of our pediatric patients treated 
with TBI at the University Hospital of Zurich from 1978–2006 
in order to analyze treatment outcome and late sequelae.
Patients and Methods
Since 1978, 32 pediatric patients (referred from the Univer-
sity Children’s Hospital Zurich) were treated with TBI at our 
institution. All patients have been treated according to stan-
dard protocols of the BFM (Berlin–Frankfurt–Münster study 
group) or SPOG (Swiss pediatric oncology group). Patients’ 
characteristics are provided in Table 1.
Records of regular follow-up of 28 patients were avail-
able for review. Mean follow-up (FU) was 34 months (range 
2–196 months). At the time of last FU, 15 patients were alive, 
while 8 had died of a recurrence, 1 of a GvHR, 2 of sepsis, 
and 2 patients died of secondary malignancy. Mean FU of the 
surviving 15 children was 56 months (12–171 months). At the 
time of last FU, 11 patients had survived TBI for more than 
36 months.
Of the patients, 18 suffered from acute lymphoblastic leu-
kemia (ALL), 5 from acute and 2 from chronic myelogenous 
leukemia, 1 from non-Hodgkin lymphoma, and 2 from ana-
plastic anemia. A total of 15 patients were referred after first 
remission and 13 patients with relapsed leukemia. Mean age at 
the time of TBI was 10 years (range 2–17 years). Transplanta-
tions with bone marrow from a related donor was performed 
in 13 children, 2 of whom were monozygotic twins, while 8 
children received bone marrow from HLA-identical unre-
lated donors and 6 received peripheral stem cells from related 
donors.
All but 2 patients (n=26) underwent fractionated TBI in 
single doses of 2–2.2 Gy up to total doses of 12–13.2 Gy, admin-
istered either once (12 patients) or twice daily (14 patients) at 
a mean low dose rate of 0.06 Gy/min (range 0.04–0.1 Gy). The 
other two patients (n=2) had been treated in the late 1970s and 
received 10 Gy in a single fraction at dose rates of 0.15 Gy/min 
and 0.035 Gy/min, respectively, resulting in an overall treat-
ment time of more than 4 hours in the latter patient.
The lungs were shielded with individualized partial trans-
mission lung blocks in order to reduce lung doses to <10 Gy. 
Thermoluminescence dosimetry (TLD) to the head, neck, 
jugulum, xiphoid, and navel were applied during at least two 
fractions. No eye shielding was performed.
One child with c-ALL received an additional boost to the 
mediastinum of 3x2 Gy. Five children with ALL received an 
additional boost to the testes of 3x2 Gy or 11x1.2 Gy, 3 of them 
also received a boost to the brain (3x2 Gy). Three children had 
received irradiation to the brain before TBI was indicated.
Follow-up examinations after TBI were routinely per-
formed in the Department of Pediatric Oncology and includ-
ed clinical assessment with measurement of height and weight, 
blood counts (including differential blood, kidney, and liver 
parameters), hormonal status at least once yearly, chest X-ray, 
electrocardiogram, and an ophthalmological control in case of 
Wachstumsstörungen mit einer Körpergrösse kleiner als die 25. Perzentile zeigten sich bei allen vor der Pubertät behandelten 
Kindern. Bei zwei eineiigen Zwillingen zeigt sich ein Verlust von 8% an Körpergrösse im Vergleich zum Zwilling.
Schlussfolgerung: Wie erwartet zeigen sich schwere Spättoxizitäten nach Ganzkörperbestrahlung mit zwei Sekundärtumoren bei 
11 Patienten, die länger als 36 Monate überlebt haben. Aber die Morbidität ist mässig nach fraktionierter Ganzkörperbestrahlung 
und der hier in fast allen Fällen verwendeten niedrigen Dosisrate. Konditionierung ohne TBI ist eine attraktive Möglichkeit, aber 
noch nicht effektiv genug um die TBI im Kindesalter ganz zu ersetzen.
Schlüsselwörter: Ganzkörperbestrahlung . Stammzelltransplantation . Dosisrate
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Table 1. Characteristics of treated patients. m: male, f: female, ALL: acute lymphoblastic leukemia, AML: acute myelogenous leukemia, CML: chronic 
myelogenous leukemia, NHL: non-Hodgkin lymphoma, AA: anaplastic anemia, TBI: total body irradiation.
Tabelle 1. Charakteristik der behandelten Patienten.
Gender Diag-
nosis
Relapsed 
leukemia at 
time of TBI
Age at time
of TBI
Transplanta-
tion
Single
dose
Total
dose
GV
HD
Secondary
malignoma
Recur-
rence
Death Follow-up 
(months)
Late effects
m ALL + 11 allogeneic bone 
marrow
 2 12 M. Hodgkin 1 1  8 secondary 
malignancy
m AML 17 allogeneic bone 
marrow
 2 12 0 0 0  87
m ALL +  5 allogeneic bone 
marrow
10 10 0 1 1
(recurrence)
 14
m AML +  2 allogeneic bone 
marrow (identi-
cal twin)
10 10 Fibrosarcoma
Colon
0 1 196 secondary 
malignancy
cataract
m ALL +  7 allogeneic bone 
marrow
 2 12 0 1 1
(recurrence)
 35
m ALL 17 allogeneic bone 
marrow
 2 12 0 171
m ALL  7 allogeneic bone 
marrow (identi-
cal twin)
 2 12 0 0 0 170 cardiomy-
opathia
m ALL + 12 allogeneic bone 
marrow
 2 12 0 1 1
(recurrence)
 29 pneumonitis
m NHL 17 allogeneic bone 
marrow
 2 12 + 0 0 0 121
f AML 16 allogeneic bone 
marrow (not 
related)
 2.2 13.2 0 0 0 108 cataract
m CML 11 allogeneic bone 
marrow (not 
related)
 2 12 0 1 1
(recurrence)
 97 hypothyre-
osis
m ALL 12 allogeneic bone 
marrow
 2 12 + 0 0 1
(sepsis)
 2
m ALL 17 allogeneic bone 
marrow
 2 12 + 0 0 0  83
f AA +  8 allogeneic 
hematopoietic 
stem cell
 2  6 0 1 1
(recurrence)
 19
f AA 17 allogeneic bone 
marrow (not 
related)
 2 12 0 0 0  62 glomerular 
nephritis
m CML 17 allogeneic bone 
marrow (not 
related)
 2.2 13.2 + 0 0 0  60 elevated liv-
er enzymes
chronic 
bronchitis
f ALL  8 allogeneic 
hematopoietic 
stem cell
 2 12 0 0 0  53 special 
school
m ALL +  7 allogeneic bone 
marrow (not 
related)
 2 12 0 0 0  35 glomerular 
nephritis
f ALL +  3  2 12 0 1 1
(recurrence)
 6
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subjective clinical impairment. In addition, surviving patients 
and the parents of 6 patients who had been lost to follow-up 
were contacted and questioned.
The end point selected for the retrospective analysis was 
overall survival (OS). Statistica version 5.5 (StatSoft, Tulsa, 
OK, USA) was used for statistical analysis. Overall survival 
was calculated from the time of first radiation fraction to the 
date of death or to the date of last FU. Patterns of survival 
were estimated by the Kaplan–Meier method. Differences be-
tween groups were assessed by log rank test (2 groups) and X2 
test (more than two groups).
Results
The 5-year OS was 60% (Figure 1); however, overall surviv-
al was significantly inferior in patients treated after relapse 
compared to those treated for newly diagnosed leukemia 
(24% versus 74% p=0.004; Figure 2). There was a trend to-
wards improved survival in patients treated with TBI for ALL 
compared to AML with a 5-year OS rate of 68% versus 46% 
(p=0.11). Interestingly, survival was better in those patients 
who had received a matched unrelated bone marrow trans-
plant, compared to those who were administered bone mar-
row or peripheral stem cells of related donors, with 5-year OS 
of 88% versus 57% and 33%, respectively. This difference 
was, however, not significant (p=0.14; Figure 3). Mean time 
of aplasia after TBI was 22 days. GvHR were observed in 7 
patients and were temporarily severe in 3. Of the severe reac-
Table 1. (continued)
Table 1. (Fortsetzung)
Gender Diag-
nosis
Relapsed 
leukemia at 
time of TBI
Age at time
of TBI
Transplanta-
tion
Single
dose
Total
dose
GV
HD
Secondary
malignoma
Recur-
rence
Death Follow-up 
(months)
Late effects
m ALL  3 allogeneic 
hematopoietic 
stem cell
2 12 0 0 0  33 glomerular 
nephritis
m ALL + 11 allogeneic 
hematopoietic 
stem cell
2 12 0 1 1
(recurrence)
 7
f AML + 12 allogeneic bone 
marrow (not 
related)
2 12 0 0 0  34 cardiomy-
opathy
m ALL  6 allogeneic 
bone marrow 
(not related)
2 12 0 0 0  28
m ALL + 12 allogeneic 
hematopoietic 
stem cell
2 12 0 1 1
(recur-
rence)
 10 hypothyre-
osis
m ALL + 12 allogeneic 
bone marrow 
(not related)
2 12 + 0 0 0  19 elevated 
liver en-
zymes
m AML  8 allogeneic 
bone marrow
2 12 + 0 0 0  11
m ALL +  5 allogeneic 
hematopoietic 
stem cell
2 12 + 0 0 1
(sepsis)
 3
m ALL 13 allogeneic 
bone marrow
2 12 0 0 0  9 optic 
nerve 
edema
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Figure 1. Overall survival after TBI in pediatric patients.
Abbildung 1. Gesamtüberleben nach Ganzkörperbestrahlung bei pä-
diatrischen Patienten.
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tions, 1 patient died within 4 weeks after transplantation of 
a candida sepsis during severe GvHR of the gastrointestinal 
tract. In 5 patients, chronic GvHR with associated slight skin 
reactions were recorded. The cumulative incidence of chronic 
GvHR reached 25% after 5 years.
Subacute effects observed were a nonfatal pneumonitis 
in one of the 2 patients treated with a single dose TBI and 2 
cases of severe acute parotitis requiring pain medication. One 
patient developed edema of the optic nerves within 2 months 
after TBI which lead to impaired sight in one eye.
Late effects (RTOG >3) observed were chronic bronchitis 
in 1 patient, cardiomyopathy in 2 patients, and severe catarac-
togenesis requiring surgery in 1 patient (48 months after TBI 
with 10 Gy in a single dose). Elevated kidney parameters with 
slight glomerular nephritis were observed in 3 patients. Elevat-
ed liver enzymes could be observed in 2 patients with GvHR.
Two children required hormones for hypothyroidism. 
All girls treated before the onset of puberty demonstrated 
elevated FSH levels and 1 required hormones to induce pu-
berty. IgF-1 was low in all patients treated before puberty, but 
growth hormones were required in only 2 patients. One patient 
was not able to attend normal school and had to be transferred 
to a special school. The other patients attended and gradu-
ated from normal schools. Growth disturbances (defined as 
a height in the lower 25th percentile) were observed in all pa-
tients treated prepubertally. In 2 patients with identical twins, 
treated at age 2 and 7 years, a loss of 8% in final height was ob-
served compared to their untreated twins. No problems with 
dentition were reported. Secondary malignancies occurred in 
2 patients (Hodgkins disease 36 months after TBI and a gas-
trointestinal fibrosarcoma 190 months after TBI).
Discussion
With a 5-year OS of 60% in all treated patients and 10-year OS 
rate of 74 % in those patients undergoing TBI after their first 
remission, our data compare well with the literature [5, 10, 13, 
24]. There are four prospective randomized studies comparing 
TBI with chemotherapy-only conditioning regimens: Blaise [5] 
reported OS rates of 75% after cyclophosphamide (Cy)/TBI 
conditioning versus 51% after chemotherapy-only (Busulfan 
(Bu)/Cy) conditioning in 101 patients treated for AML in first 
remission. Ringden [24] reported for the Nordic Bone Mar-
row Transplantation Group a 3-year survival rate of 76% after 
conditioning with TBI/Cy compared to 62% after condition-
ing with Bu/Cy in 167 patients with leukemia (~40% AML, 
35% CML, 25% ALL). Seattle [10] and the French Society 
of Bone Marrow transplantation [13] found no difference or 
clear advantages for either regimen (Cy/TBI versus Cy/BU) in 
patients with CML and reported a 3-year OS rate of 80% and 
a 5-year OS rate of about 60%. Granados et al. [17] report on 
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Figure 2. Overall survival after TBI for first diagnosis or recurrent dis-
ease.
Abbildung 2. Gesamtüberleben nach Ganzkörperbestrahlung bei Erstdi-
agnose oder nach Rezidiv.
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Figure 3. Overall survival after matched non-related donor and related 
donor (p=n.s.).
Abbildung 3. Überleben nach Transplantation mit passendem nicht-
verwandtem und verwandtem Spender (p=n.s.).
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a retrospective analysis of 156 patients with ALL transplanted 
after either TBI-based or chemotherapy-only conditioning 
and found a statistically significant improved 6-year event-
free survival of 43% versus 22% favoring the TBI regimen. 
Despite the well-known late sequelae, TBI-based regimens 
continue to be widely accepted, especially in ALL (above the 
age of 2 years) and remain the mainstay in conditioning treat-
ment.
Side effects and complications of TBI have been exten-
sively studied and yet remain difficult to distinguish from side 
effects of high-dose chemotherapy. In pediatric patients, es-
pecially high rates of late sequelae following TBI have been 
observed in studies with long median follow-up times of over 
3 years [23, 29]. Consistent with our data, hypothyroidism was 
observed in 12% of pediatric patients after a median FU of 
3 years. After a median FU of 12 years, mild cataracts were 
recorded in 80% of patients, while severe cataracts were ob-
served in 20% after 6 years. However, in leukemia patients 
cataract incidence is also influenced by cortisone medication 
and was observed in 12% of AML patients treated without 
TBI [28].
Interestingly, we detected no clinically or radiologically 
relevant interstitial pneumonitis (IP) in low-dose TBI and only 
one case of chronic bronchiolitis. TBI with lung shielding and 
reduced dose rates in other retrospective analyses resulted in 
IP rates as low as 2% [26, 27]. Busulfan is also known to impair 
lung function and resulted in lower mean vital capacities than 
fractionated TBI in a retrospective analysis of 80 children af-
ter a median follow-up of 4 years [9]. Compared to these data, 
the incidence of late side effects in our 11 long-term survivors 
treated with low-dose rate TBI remains low, with only one 
cataract and two clinically manifest cases of hypothyroidism. 
The cases of cardiomyopathy, interstitial bronchiolitis, and 
decreased glomerular filtration rates are also possibly attrib-
utable to chemotherapy.
With respect to organ dysfunction, long-term morbidity 
and mortality, the Bone Marrow Transplant Survivor Study [3] 
demonstrated a protective effect provided by TBI compared 
to the chemotherapy-only regimen in over 850 patients who 
had survived autologous hematopoietic stem cell transplanta-
tion for more than 2 years. Robin et al. [25] found that TBI, 
compared to chemotherapy-only conditioning, was mainly as-
sociated with cataracts, endocrine dysfunction, secondary can-
cers, and late severe bacterial infection, whereas pulmonary 
and cardiac problems seemed to be associated with chemo-
therapy and GvHR. There were no cases of late severe bacte-
rial infections in our small cohort of long-term survivors, but 2 
patients died secondary to sepsis during the time of aplasia. In 
addition, aplasia duration in our patients and in the literature 
was not longer than after conditioning regimens without TBI. 
We found reduced glomerular filtration rates in 3 patients, 
which were most likely induced by chemotherapy. Miralbell et 
al. [19] actually reported an inverse correlation between renal 
function and the prescribed TBI dose, and attributed this to 
the use of nephrotoxic contrast agents at the time of treatment 
planning with the aim of improving kidney shielding. Hypo-
thyroidism is a common late sequela of conditioning with and 
without TBI and has been observed in over 70% of patients 
5 years after TBI; supplementation was necessary in 10% of 
those affected [2], which is consistent with our findings.
Two of our patients died as a result of secondary malig-
nancies – one hematological disease which occurred earlier 
and one solid tumor which occurred more than 10 years af-
ter transplantation. Recently published data about secondary 
cancer after TBI showed a cumulative incidence of solid tu-
mors of 1.7% and 8.2% after 5 and 10 years, respectively [21]. 
Bhatia et al. [4] observed a cumulative incidence of 10% for 
solid cancer 10 years after conditioning with and without TBI, 
with a higher risk for younger patients and a higher risk for 
certain cancers, e.g., thyroid, oral cavity, liver cancer, in pa-
tients receiving radiation therapy. Our patients definitely re-
main at a life-long high risk for secondary cancers and should 
attend careful screening.
Conclusion
Low-dose rate TBI using conventional fractionation results 
in acceptable early and late toxicity with a demonstrated low 
risk for cataracts, interstitial pneumonitis, and veno-occlusive 
disease. It also yields favorable OS rates. Therefore, despite 
its late sequelae, TBI remains warranted in certain pediatric 
patients (over 2 years of age) undergoing transplantation, giv-
en that chemotherapy-only conditioning regimens have not 
proven to be equally effective in the current literature. On-
going studies may show a paradigm shift in the future. Obvi-
ously, conditioning with TBI or chemotherapy for bone mar-
row transplantation in pediatric patients should be exclusively 
performed within studies and at specialized centers.
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